{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:24:51Z","timestamp":1793651091425,"version":"4.5.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1136\/ard-2023-223916","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T17:25:21Z","timestamp":1686590721000},"page":"1130-1141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme"],"prefix":"10.1016","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct02706873","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02675426","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02629159","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02706951","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02706847","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03086343","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Roy","family":"Fleischmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1768-7019","authenticated-orcid":false,"given":"Christina","family":"Charles-Schoeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3029-8739","authenticated-orcid":false,"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Palac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanne","family":"Dilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Strengholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-223916_bib1","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/art.41906","article-title":"A decade of JAK inhibitors: what have we learned and what may be the future","volume":"73","author":"Liu","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223916_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223916_bib4","author":"US Food and Drug Administration"},{"key":"10.1136\/ard-2023-223916_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib6","author":"European Medicines Agency"},{"key":"10.1136\/ard-2023-223916_bib7","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223916_bib8","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223916_bib9","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223916_bib10","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or Abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223916_bib11","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223916_bib12","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223916_bib13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14397595.2020.1782049","article-title":"A review of upadacitinib in rheumatoid arthritis","volume":"30","author":"Tanaka","year":"2020","journal-title":"Modern Rheumatology"},{"key":"10.1136\/ard-2023-223916_bib14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib15","doi-asserted-by":"crossref","first-page":"e002012","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-223916_bib16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of Baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-223916_bib18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/annrheumdis-2022-eular.1182","article-title":"POS0237 major adverse cardiovascular events, Malignancie, and venous thromboembolism by baseline cardiovascular risk: A post hoc analysis of oral surveillance [Abstract]","volume":"81","author":"Buch","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib19","author":"European Medicines Agency [Internet]"},{"key":"10.1136\/ard-2023-223916_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib21","first-page":"19","article-title":"Cardiovascular risks associated with gender and aging","volume":"6","author":"Rodgers","year":"2019","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1136\/ard-2023-223916_bib22","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","article-title":"Associations of baseline use of biologic or targeted synthetic Dmards with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry","volume":"80","author":"Sparks","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib23","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1136\/annrheumdis-2021-221146","article-title":"\u201cCorrespondence on \u201cassociations of baseline use of biologic or targeted synthetic Dmards with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician Registry\u201d\u201d","volume":"82","author":"van Vollenhoven","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib24","article-title":"Response to: correspondence on \u201cassociations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis\u201d by sparks et al","author":"Sparks","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/14787210.2022.2004120","article-title":"Janus kinase inhibitors for hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials","volume":"20","author":"Lan","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1136\/ard-2023-223916_bib26","article-title":"Janus kinase inhibitors for the treatment of COVID-19","volume":"6","author":"Kramer","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ard-2023-223916_bib27","author":"AbbVie [Internet]"},{"key":"10.1136\/ard-2023-223916_bib28","author":"AbbVie [Internet"},{"key":"10.1136\/ard-2023-223916_bib29","doi-asserted-by":"crossref","first-page":"e002871","DOI":"10.1136\/rmdopen-2022-002871","article-title":"Antibody response to the COVID-19 ChAdOx1nCov-19 and Bnt162B vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study [RESCUE 2]","volume":"9","author":"Tran","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-223916_bib30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2023-223916_bib31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2022-eular.879","article-title":"OP0264 impact of baseline cardiovascular risk on the incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme [Abstract]","volume":"81","author":"Dougados","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib32","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib33","doi-asserted-by":"crossref","first-page":"e001374","DOI":"10.1136\/rmdopen-2020-001374","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research","volume":"6","author":"Kerschbaumer","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-223916_bib34","doi-asserted-by":"crossref","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, Ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-223916_bib35","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib36","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib37","first-page":"201","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2023-223916_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","article-title":"Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden","volume":"80","author":"Molander","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13075-017-1482-y","article-title":"The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs","volume":"19","author":"Cho","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-223916_bib41","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2013-204531","article-title":"The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients","volume":"74","author":"Arts","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223916_bib42","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/annrheumdis-2014-206411","article-title":"The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease","volume":"75","author":"Myasoedova","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724423091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724423091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-223916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:50:14Z","timestamp":1739523014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724423091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0003496724423091"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-223916","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-223916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}